Inventor · disambiguated record
Zhenfan Yang
Also filed as: YANG ZHENFAN
12 granted patents·11 pending applications·13 citations·filing 2014–2023
86Inventor score
Top patents by PatentIndex Score
23 records- 0193US10822334B2ErbB receptor inhibitorsDIZAL JIANGSU PHARMACEUTICAL CO LTD·Filed 2020·Granted Nov 3, 2020·4 cites·6 claims
- 0287US11007198B2ErbB/BTK inhibitorsDIZAL JIANGSU PHARMACEUTICAL CO LTD·Filed 2020·Granted May 18, 2021·2 cites·5 claims
- 0383US10898481B2Pyrazine compounds and uses thereofDIZAL JIANGSU PHARMACEUTICAL CO LTD·Filed 2020·Granted Jan 26, 2021·1 cites·6 claims
- 0482US11504375B2ErbB/BTK inhibitorsDIZAL JIANGSU PHARMACEUTICAL CO LTD·Filed 2021·Granted Nov 22, 2022·1 cites·23 claims
- 0582US10858365B2Triazolo-pyrimidine compounds and uses thereofDIZAL JIANGSU PHARMACEUTICAL CO LTD·Filed 2020·Granted Dec 8, 2020·1 cites·9 claims
- 0679US9066979B2Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptorASTRAZENECA AB·Filed 2014·Granted Jun 30, 2015·3 cites·16 claims
- 0775US11896597B2ErbB/BTK inhibitorsDIZAL JIANGSU PHARMACEUTICAL CO LTD·Filed 2022·Granted Feb 13, 2024·0 cites·20 claims
- 0873US2023135068A1Pyrazine compounds and uses thereofDIZAL JIANGSU PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 0973US2025057850A1Erbb/btk inhibitorsDIZAL JIANGSU PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 1071US9375432B2Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptorASTRAZENECA AB·Filed 2015·Granted Jun 28, 2016·1 cites·18 claims
- 1166US11571420B2Pyrazine compounds and uses thereofDIZAL JIANGSU PHARMACEUTICAL CO LTD·Filed 2020·Granted Feb 7, 2023·0 cites·22 claims
- 1261US11629147B2Triazolo-pyrimidine compounds and uses thereofDIZAL JIANGSU PHARMACEUTICAL CO LTD·Filed 2020·Granted Apr 18, 2023·0 cites·24 claims
- 1361US11447492B2ERBB receptor inhibitorsDIZAL JIANGSU PHARMACEUTICAL CO LTD·Filed 2020·Granted Sep 20, 2022·0 cites·15 claims
- 1461US2022411422A1Erbb receptor inhibitorsDIZAL JIANGSU PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 1561US2025346616A1Rock inhibitors and uses thereofDIZAL JIANGSU PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 1659US9718806B2Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptorASTRAZENECA AB·Filed 2016·Granted Aug 1, 2017·0 cites·13 claims
- 1756US2018016259A1Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptorASTRAZENECA AB·Filed 2017·Application pending·0 cites
- 1855US2025197377A1Novel pharmaceutical salts and polymorphic forms of an erbb and btk inhibitorDIZAL JIANGSU PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 1952US2023055566A1Novel anti-fgfr2b antibodiesDIZAL JIANGSU PHARMACEUTICAL CO LTD·Filed 2020·Application pending·0 cites
- 2052US2023052256A1Novel anti-fgfr2b antibodiesDIZAL JIANGSU PHARMACEUTICAL CO LTD·Filed 2020·Application pending·0 cites
- 2152US2023052680A1Novel anti-fgfr2b antibodiesDIZAL JIANGSU PHARMACEUTICAL CO LTD·Filed 2020·Application pending·0 cites
- 2250US2022242884A1Dna-dependent protein kinase inhibitorDIZAL JIANGSU PHARMACEUTICAL CO LTD·Filed 2020·Application pending·0 cites
- 2349US2023122807A1Btk inhibitorsDIZAL JIANGSU PHARMACEUTICAL CO LTD·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Zhenfan Yang files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →